BeiGene, Ltd. (BGNE)
Last Price$226.70.0%
Market Cap$1,846.9M
LTM P/E
(2.1x)
EPS growth
(71.8%)
PEGY
0.0x
Peter Lynch Fair Value
$7,585.1
Undervalued (Peter Lynch formula)
3,245.7%
Stock quality
5/10
Good
BGNE Peter Lynch Fair Value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
BGNE EPS growth & Dividend Yield
Crunching data... Almost there!
BGNE vs Peer Set: Peter Lynch Fair Value Comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for BGNE
Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value
FAQ
What is BeiGene, Ltd. fair value by Peter Lynch formula?
As of Jan 29, 2025, BeiGene, Ltd.'s fair value using the Peter Lynch formula is $7,585.1 per share. The current price of $226.7 suggests BeiGene, Ltd. may be undervalued by this metric.
What is BeiGene, Ltd. Price to Earnings (P/E) ratio?
As of Jan 29, 2025, BeiGene, Ltd.'s P/E ratio is (2.1x). This is calculated by dividing the current share price of $226.7 by the Earnings per Share (EPS) for the trailing twelve months, which is ($7.7). The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
What is BeiGene, Ltd. earnings per share (EPS)?
BeiGene, Ltd. earnings per share (EPS) for the twelve months ending Jan 29, 2025, was ($7.7), a (71.8%) growth year-over-year.